← Eichor
Condition: Ureteral Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ureteral Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07125547Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06598761Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Mic
Phase N/A · 1 location(s) · Yonsei University · NCT04625556uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Phase N/A · 22 location(s) · UroGen Pharma Ltd. · NCT05874921Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery
Phase 3 · 3 location(s) · Hans Bahlmann · NCT06349668Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
NA · 2 location(s) · Peking University First Hospital · NCT06652022Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiri
Phase 4 · 5 location(s) · Rigshospitalet, Denmark · NCT06709196Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
NA · 2 location(s) · Thomas Jefferson University · NCT07234968Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulati
Phase N/A · 1 location(s) · Yonsei University · NCT04197414Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Phase N/A · 2 location(s) · Xuesong Li · NCT06120387FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
NA · 2 location(s) · Rabin Medical Center · NCT05992363Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2 · 1 location(s) · Nagoya University · NCT06983210A Study of Surgical Techniques During Cystectomy
Phase 3 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06703476Integrated Cancer Repository for Cancer Research
Phase N/A · 42 location(s) · University of Nebraska · NCT02012699ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Phase N/A · 57 location(s) · Guardant Health, Inc. · NCT05059444Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and
Phase 4 · 1 location(s) · Mayo Clinic · NCT06764095A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.